NL300362I1 - Vaccin omvattende olie/water-emulsie met tocoferolen squaleen - Google Patents

Vaccin omvattende olie/water-emulsie met tocoferolen squaleen

Info

Publication number
NL300362I1
NL300362I1 NL300362C NL300362C NL300362I1 NL 300362 I1 NL300362 I1 NL 300362I1 NL 300362 C NL300362 C NL 300362C NL 300362 C NL300362 C NL 300362C NL 300362 I1 NL300362 I1 NL 300362I1
Authority
NL
Netherlands
Prior art keywords
oil
water emulsion
tocopherols
squalene
vaccine
Prior art date
Application number
NL300362C
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NL300362I1 publication Critical patent/NL300362I1/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Fats And Perfumes (AREA)
  • Edible Oils And Fats (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NL300362C 1993-12-23 2008-10-22 Vaccin omvattende olie/water-emulsie met tocoferolen squaleen NL300362I1 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939326253A GB9326253D0 (en) 1993-12-23 1993-12-23 Vaccines

Publications (1)

Publication Number Publication Date
NL300362I1 true NL300362I1 (nl) 2009-01-05

Family

ID=10747069

Family Applications (2)

Application Number Title Priority Date Filing Date
NL300362C NL300362I1 (nl) 1993-12-23 2008-10-22 Vaccin omvattende olie/water-emulsie met tocoferolen squaleen
NL300363C NL300363I1 (nl) 1993-12-23 2008-10-22 Vaccin omvattende olie/water-emulsie met tocoferolen squaleen

Family Applications After (1)

Application Number Title Priority Date Filing Date
NL300363C NL300363I1 (nl) 1993-12-23 2008-10-22 Vaccin omvattende olie/water-emulsie met tocoferolen squaleen

Country Status (23)

Country Link
US (5) US6146632A (nl)
EP (4) EP1327451B1 (nl)
JP (3) JP4125781B2 (nl)
KR (1) KR100350965B1 (nl)
CN (1) CN1086589C (nl)
AT (3) ATE359818T1 (nl)
AU (3) AU1316495A (nl)
CA (1) CA2179779C (nl)
CY (2) CY2530B1 (nl)
DE (5) DE122008000054I1 (nl)
DK (3) DK1327451T3 (nl)
ES (3) ES2129801T3 (nl)
GB (1) GB9326253D0 (nl)
GR (1) GR3029750T3 (nl)
HK (3) HK1012243A1 (nl)
LU (2) LU91486I2 (nl)
NL (2) NL300362I1 (nl)
NZ (2) NZ277802A (nl)
PT (2) PT1327451E (nl)
SG (2) SG49257A1 (nl)
SI (3) SI0735898T1 (nl)
WO (2) WO1995017209A1 (nl)
ZA (1) ZA9410176B (nl)

Families Citing this family (570)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
WO1997025429A1 (en) 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
US20060024301A1 (en) * 1997-02-25 2006-02-02 Corixa Corporation Prostate-specific polypeptides and fusion polypeptides thereof
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) * 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP2050465B1 (en) * 1997-08-29 2014-06-11 Antigenics Inc. Compositions comprising the adjuvant QS-21 and polysorbate or cyclodextrin as excipient
EP1279401B1 (en) * 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
ATE462788T1 (de) 1998-02-05 2010-04-15 Glaxosmithkline Biolog Sa Verfahren zur reinigung oder herstellung der mage protein
ATE339223T1 (de) * 1998-03-09 2006-10-15 Glaxosmithkline Biolog Sa Kombinierte impfstoffzusammensetzungen
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
GB9806095D0 (en) * 1998-03-20 1998-05-20 Smithkline Beecham Biolog Novel compounds
AU753995B2 (en) 1998-04-07 2002-10-31 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
AU755445B2 (en) * 1998-05-07 2002-12-12 Corixa Corporation Adjuvant composition and methods for its use
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
IL141044A0 (en) 1998-08-07 2002-02-10 Univ Washington Innunological herpes simplex virus antigens and methods for use thereof
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CN101926993B (zh) * 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
GB9822714D0 (en) 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
CA2354232A1 (en) 1998-12-08 2000-06-15 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1137777B1 (en) 1998-12-08 2011-10-05 GlaxoSmithKline Biologicals s.a. Novel compounds derived from neisseria meningitidis
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
MXPA01007760A (es) * 1999-02-01 2003-06-24 Eisai Co Ltd Compuesto adyuvante inmunologico.
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
GB2348132B (en) * 1999-03-02 2004-08-04 Nedaa Abdul-Ghani Nasif Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils
DE60031383T2 (de) 1999-03-11 2007-11-15 Glaxosmithkline Biologicals S.A. Verwendung von casb618 polynucleotide und polypeptide
AU3164600A (en) 1999-03-12 2000-10-04 Smithkline Beecham Biologicals (Sa) Novel compounds
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
EP1880735A3 (en) * 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccine
CA2368014A1 (en) * 1999-03-26 2000-10-05 Smithkline Beecham Biologicals S.A. Casb619 involved in colon cancers
KR20020007354A (ko) 1999-04-02 2002-01-26 길리스 스티브 폐암의 치료 및 진단에 유용한 화합물 및 방법
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
EP2322210A1 (en) 1999-04-19 2011-05-18 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
BR0010539A (pt) * 1999-05-13 2002-02-19 American Cyanamid Co Composição antigênica, e, método para incrementar a capacidade de uma composição antigênica
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
AU1013701A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Modified gp100 and uses thereof
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
SI1265915T1 (sl) 2000-02-23 2011-02-28 Glaxosmithkline Biolog Sa Nove spojine
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
ES2309064T3 (es) * 2000-04-13 2008-12-16 Corixa Corporation Composiciones inmunoestimulantes que comprenden un fosfato de aminoalquil glucosaminida y qs-21.
EP2192128A3 (en) 2000-04-21 2010-09-22 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
AU2001268472A1 (en) * 2000-06-16 2002-01-02 Smith Kline Beecham Corporation Icp27-binding polynucleotides
DK2133100T3 (da) 2000-06-20 2012-01-23 Corixa Corp MTB32A-Antigen af Mycobacterium tuberculosis med inaktiveret aktivt sted og fusionsproteiner deraf
ATE396265T1 (de) 2000-06-28 2008-06-15 Corixa Corp Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
SI1946769T1 (sl) 2000-06-29 2012-07-31 Smithkline Beecham Biolog Sestavek multivalentnega cepiva z zmanjšanim odmerkom Haemophilus influenzae tipa B
JP4230765B2 (ja) 2000-07-31 2009-02-25 エーザイ株式会社 免疫アジュバント化合物、組成物、およびその使用方法
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
EP2266603B1 (en) * 2000-10-18 2012-09-12 GlaxoSmithKline Biologicals S.A. Tumour vaccines
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
US20020094337A1 (en) * 2000-11-16 2002-07-18 University Of Maryland, Baltimore Prevention of recurrent viral disease
AU3768902A (en) 2000-11-29 2002-06-11 Xy Inc System to separate frozen-thawed spermatozoa into x-chromosome bearing and y-chromosome bearing populations
ES2397627T3 (es) 2000-12-07 2013-03-08 Novartis Vaccines And Diagnostics, Inc. Retrovirus endógenos regulados por aumento en el cáncer de próstata
WO2002058727A2 (en) * 2001-01-26 2002-08-01 Walter Reed Army Institute Of Research Recombinant plasmodium falciparum merozoite protein-1/42 vaccine
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP1361890B1 (en) 2001-02-23 2011-03-30 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP1417236A4 (en) 2001-07-10 2010-03-17 Corixa Corp COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ENCAPSULATED PROTEINS AND ADJUVANTS IN MICROSPHERES
EP1420818B1 (en) * 2001-07-26 2018-11-21 Otago Innovation Limited Antigenic compositions
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
EP2224012B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US7030094B2 (en) * 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
ES2607431T3 (es) 2002-02-20 2017-03-31 Glaxosmithkline Biologicals Sa Micropartículas con moléculas que contienen polipéptidos adsorbidos
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
EP2330113B1 (en) 2002-04-19 2016-06-29 The Governing Council Of The University Of Toronto Immunological methods and compositions for the treatment of Alzheimer's disease
CA2489292A1 (en) 2002-06-13 2003-12-24 Chiron Corporation Vectors for expression of hml-2 polypeptides
DE60324678D1 (de) 2002-07-18 2008-12-24 Univ Washington N t-lymphozyten und damit identifizierte hsv-antigene
WO2004012751A1 (ja) * 2002-08-02 2004-02-12 Sumitomo Pharmaceuticals Company, Limited 細菌細胞壁骨格成分製剤
WO2004014419A1 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7169548B2 (en) 2002-09-13 2007-01-30 Xy, Inc. Sperm cell processing and preservation systems
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
RU2356577C9 (ru) 2002-10-23 2009-08-10 Глаксосмитклайн Байолоджикалс С.А. Способы вакцинации против малярии
AU2003288660A1 (en) 2002-11-15 2004-06-15 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
WO2004061423A2 (en) 2003-01-06 2004-07-22 Wyeth Compositions and methods for diagnosing and treating colon cancers
CA3042073C (en) 2003-01-30 2022-09-13 Novartis Vaccines And Diagnostics S.R.L. Injectable vaccines against multiple meningococcal serogroups
ES2586482T3 (es) 2003-03-28 2016-10-14 Inguran, Llc Aparato, métodos y procesos para clasificar partículas y para proporcionar esperma animal clasificado por sexo
MXPA05010697A (es) 2003-04-04 2005-12-12 Pfizer Prod Inc Emulsiones de aceite en agua microfluidizadas y composiciones de vacunas.
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7731967B2 (en) * 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
JP5557415B2 (ja) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
CA2885040C (en) 2003-10-02 2018-10-30 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
DE602004028262D1 (de) 2003-10-02 2010-09-02 Glaxosmithkline Biolog Sa B. pertussis antigene und ihre verwendung bei der vakzinierung
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1730182B1 (en) 2004-02-05 2015-04-29 The Ohio State University Research Foundation Chimeric vegf peptides
JP5600375B2 (ja) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド インフルエンザウイルスワクチン
EP1741438A4 (en) * 2004-04-22 2009-08-26 Dainippon Sumitomo Pharma Co PHARMACEUTICAL PREPARATION CONTAINING SKELETAL COMPONENT OF BACTERIAL CELL WALL
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
SI1740217T1 (sl) 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
WO2006078294A2 (en) 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
CA2567597C (en) 2004-05-25 2014-03-18 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
AU2005249212B2 (en) * 2004-05-28 2010-05-20 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US8085126B2 (en) * 2004-07-27 2011-12-27 Honeywell International Inc. Identification with RFID asset locator for entry authorization
JP2008508320A (ja) 2004-07-29 2008-03-21 カイロン コーポレイション Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US20080085289A1 (en) 2004-09-22 2008-04-10 Cindy Castado Immunogenic Composition
US8846051B2 (en) 2004-10-08 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by deoptimization of synonymous codons
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
TW200635607A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
PL2682126T3 (pl) 2005-01-27 2017-07-31 Children's Hospital & Research Center At Oakland Szczepionki pęcherzykowe oparte na GNA1870 dla szerokiego spektrum ochrony przeciwko chorobom spowodowanym przez Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
PL1858920T3 (pl) 2005-02-18 2016-12-30 Białka i kwasy nukleinowe z Escherichia coli związane z zapaleniem opon mózgowych/sepsą
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
DK1861120T3 (en) 2005-03-23 2016-07-25 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
GB0506001D0 (en) * 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Novel use
EA014527B1 (ru) 2005-03-31 2010-12-30 Глаксосмитклайн Байолоджикалс С.А. Вакцины против хламидиоза
CN101355928B (zh) 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
BRPI0611347A2 (pt) 2005-04-29 2010-08-31 Glaxosmithline Biolog S A composicão farmacêutica, usos de uma proteìna de fusão mtb72f ou um fragmento imunogênico da mesma, e, de um ácido nucléico
JP5222134B2 (ja) 2005-06-15 2013-06-26 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション Ｈｅｒ−２ペプチド
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
CN101365714A (zh) 2005-07-01 2009-02-11 福赛特儿童口腔医院 结核抗原的检测分析及疫苗
KR20080080087A (ko) * 2005-09-30 2008-09-02 티티아이 엘뷰 가부시키가이샤 신규 약학 담체를 이용한 경피 약물 전달시스템, 장치 및방법
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
JP2009509634A (ja) * 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 官能基化マイクロニードル経皮薬剤送達システム、装置及び方法
KR20080066712A (ko) * 2005-09-30 2008-07-16 티티아이 엘뷰 가부시키가이샤 관능화된 미세바늘 경피 약물 전달 시스템, 장치 및 방법
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ567979A (en) 2005-11-04 2012-02-24 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7
JP2009514850A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
DK2368572T3 (da) 2005-11-04 2020-05-25 Seqirus Uk Ltd Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
EA014028B1 (ru) * 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP1948232A4 (en) * 2005-11-18 2010-09-22 Univ Ohio State Res Found VIRAL GENE PRODUCTS AND VACCINATION METHODS FOR PREVENTING ASSOCIATED VIRAL DISEASES
WO2007061964A1 (en) * 2005-11-18 2007-05-31 3M Innovative Properties Company Methods for coating microneedles
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR101365001B1 (ko) 2005-12-22 2014-02-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 폐렴구균 다당류 컨쥬게이트 백신
WO2007079190A2 (en) * 2005-12-29 2007-07-12 Tti Ellebeau, Inc. Device and method for enhancing immune response by electrical stimulation
MY150105A (en) 2006-01-17 2013-11-29 Forsgren Arne A novel surface exposed haemophilus influenzae protein (protein e; pe)
CA2640248A1 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg. Influenza vaccines containing hemagglutinin and matrix proteins
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
US20100068223A1 (en) 2006-03-24 2010-03-18 Hanno Scheffczik Storage of Influenza Vaccines Without Refrigeration
BRPI0710023A2 (pt) 2006-03-30 2011-08-02 Embrex Inc métodos e composições para a vacinação de aves domésticas
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
TW200817680A (en) 2006-06-02 2008-04-16 Glaxosmithkline Biolog Sa Method
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
CA2654709A1 (en) 2006-06-12 2007-12-21 Nathalie Devos Neisseria meningitidis lipooligosaccharide vaccine
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
WO2008094183A2 (en) * 2006-07-11 2008-08-07 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
SG173363A1 (en) 2006-07-18 2011-08-29 Glaxosmithkline Biolog Sa Vaccines for malaria
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
GB2453475B (en) 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
JP5265545B2 (ja) * 2006-09-01 2013-08-14 シーエスエル、リミテッド 免疫応答を誘発または誘導する方法
PL2097102T3 (pl) 2006-09-07 2012-10-31 Glaxosmithkline Biologicals Sa Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
MX2009002408A (es) 2006-09-11 2009-03-20 Novartis Ag Elaboracion de vacunas para el virus de la influenza sin utilizar huevos.
US20090263422A1 (en) 2006-09-15 2009-10-22 Emmanuel Jules Hanon Influenza vaccine
EP2486938B1 (en) 2006-09-26 2018-05-09 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
BRPI0717219B8 (pt) 2006-10-12 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, e, uso de uma composição imunogênica
EP2086582B1 (en) 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccine comprising an oil in water emulsion adjuvant
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
MX362698B (es) 2007-03-02 2019-02-01 Glaxosmithkline Biologicals Sa Metodo novedoso y composiciones.
BRPI0809926B8 (pt) 2007-04-04 2021-05-25 Infectious Disease Res Inst composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
US20100074918A1 (en) 2007-05-02 2010-03-25 Jan Poolman Vaccine
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
PT2167121E (pt) 2007-06-26 2015-12-02 Glaxosmithkline Biolog Sa Vacina compreendendo conjugados de polissacáridos capsulares de streptococcus pneumoniae
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EA017887B1 (ru) 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Полимерные мультиэпитопные вакцины против гриппа
EP2185577A4 (en) 2007-08-03 2010-09-22 Harvard College CHLAMYDIA ANTIGENS
EP2190470B1 (en) 2007-08-13 2017-12-13 GlaxoSmithKline Biologicals SA Vaccines
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
AU2008300397A1 (en) 2007-09-17 2009-03-26 Glaxosmithkline Biologicals S.A. Improved detection of MAGE-A expression
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8637053B2 (en) 2007-12-03 2014-01-28 President And Fellows Of Harvard College Chlamydia antigens
CA2707247A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition
EP3067048B1 (en) * 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
AU2008352942B2 (en) 2007-12-19 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PL2235046T3 (pl) 2007-12-21 2012-12-31 Novartis Ag Zmutowane formy streptolizyny O
US8092813B1 (en) 2007-12-28 2012-01-10 Novartis Ag Polychlorinated biphenyls and squalene-containing adjuvants
BRPI0907843A2 (pt) 2008-02-21 2015-08-04 Novartis Ag Polipeptídeos de fhbp menigocócicos
CA2717870A1 (en) 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
CA2720268A1 (en) * 2008-04-09 2009-10-15 Ventria Bioscience Production of ospa for lyme disease control
RS54306B1 (en) * 2008-04-16 2016-02-29 Glaxosmithkline Biologicals S.A. THE VACCINE
EP3329931B1 (en) 2008-04-18 2022-06-08 The General Hospital Corporation Immunotherapies employing self-assembling vaccines
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANOEMULSION VACCINES
ES2588913T3 (es) 2008-06-04 2016-11-07 The Chemo-Sero-Therapeutic Research Institute Uso de una partícula vírica de encefalitis japonesa como adyuvante
CN102123724B (zh) 2008-06-19 2018-05-01 变异生技公司 治疗流行性感冒的组合物和方法
AU2009276304B2 (en) * 2008-08-01 2012-10-11 Gamma Vaccines Pty Limited Influenza vaccines
CA2735404C (en) 2008-08-28 2013-04-16 Novartis Ag Production of squalene from hyper-producing yeasts
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010036945A2 (en) 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
GB0822001D0 (en) * 2008-12-02 2009-01-07 Glaxosmithkline Biolog Sa Vaccine
JP2012510289A (ja) 2008-12-03 2012-05-10 プロティア ワクチン テクノロジーズ リミテッド グルタミルｔＲＮＡ合成酵素（ＧｔＳ）フラグメント
EP2376108B1 (en) 2008-12-09 2017-02-22 Pfizer Vaccines LLC IgE CH3 PEPTIDE VACCINE
ES2675771T3 (es) 2008-12-16 2018-07-12 Ology Bioservices, Inc. Producción de vacunas contra el virus de la gripe
MX2011007456A (es) 2009-01-12 2011-08-03 Novartis Ag Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
JP5642712B2 (ja) 2009-02-10 2014-12-17 ノバルティス アーゲー 少ない量のスクアレンを含むインフルエンザワクチン
KR101738704B1 (ko) * 2009-02-17 2017-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 알루미늄-비함유 아주반트를 포함하는 불활성화 뎅기 바이러스 백신
EP2403526B1 (en) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia antigens
CN102575284A (zh) 2009-03-17 2012-07-11 MDx健康公司 改进的基因表达检测
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
CA3154626A1 (en) 2009-04-14 2010-10-21 Glaxosmithkline Biologicals S.A. Compositions for immunising against staphylococcus aureus
BRPI1014494A2 (pt) 2009-04-30 2016-08-02 Coley Pharm Group Inc vacina pneumocócica e usos da mesma
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
JP2012528106A (ja) 2009-05-27 2012-11-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃａｓｂ７４３９構築物
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
WO2010146414A1 (en) 2009-06-15 2010-12-23 National University Of Singapore Influenza vaccine, composition, and methods of use
ES2566646T3 (es) 2009-06-16 2016-04-14 The Regents Of The University Of Michigan Vacunas en nanoemulsión
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2767392C (en) 2009-07-06 2017-03-14 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2767536A1 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
RU2585227C2 (ru) 2009-07-15 2016-05-27 Новартис Аг Композиции белка f rsv и способы их получения
JP2012532626A (ja) 2009-07-16 2012-12-20 ノバルティス アーゲー 無毒化されたＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原
CN103977394B (zh) 2009-07-17 2016-03-09 翰林大学校产学协力团 包含脂质体包胶的寡核苷酸和表位的免疫刺激性组合物
CN102596236B (zh) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011024072A2 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
SG10201401516XA (en) 2009-09-03 2014-10-30 Pfizer Vaccines Llc Pcsk9 vaccine
HUE030664T2 (en) * 2009-09-10 2017-05-29 Merial Inc New vaccine formulations containing saponin-containing adjuvant
KR20120081587A (ko) 2009-09-10 2012-07-19 노파르티스 아게 기도 질병에 대한 조합 백신
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
WO2011138636A1 (en) 2009-09-30 2011-11-10 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
SG10201505023TA (en) 2009-10-09 2015-07-30 Cbio Ltd Chaperonin 10 Variants
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
JP5960055B2 (ja) 2009-10-27 2016-08-02 ノバルティス アーゲー 改変髄膜炎菌ｆＨＢＰポリペプチド
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US20110159031A1 (en) 2009-12-22 2011-06-30 Baxter International Inc. Vaccine to Influenza A Virus
RU2581020C2 (ru) 2009-12-22 2016-04-10 Селлдекс Терапьютикс, Инк. Композиции вакцин
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011110635A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Immunogenic composition
AU2011224245B2 (en) 2010-03-11 2014-12-04 Immune Design Corp. Vaccines for influenza
KR20130063493A (ko) 2010-03-26 2013-06-14 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｉｖ 백신
AU2011238670B2 (en) 2010-03-30 2015-04-23 Children's Hospital & Research Center Oakland Factor H binding proteins (FHBP) with altered properties and methods of use thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
BR112012025364A2 (pt) 2010-04-07 2015-09-22 Novartis Ag método para geração de partícula semelhante a vírus de parvovírus b19
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
RU2607024C2 (ru) 2010-06-04 2017-01-10 УАЙТ ЭлЭлСи Вакцины streptococcus pneumoniae
CA2798837A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US9610248B2 (en) 2010-07-06 2017-04-04 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
JP2013533745A (ja) 2010-07-06 2013-08-29 ノバルティス アーゲー ノロウイルスに由来する免疫原性組成物および方法
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US20130259948A1 (en) 2010-09-21 2013-10-03 National Institute Of Immunology Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
SG188624A1 (en) 2010-09-27 2013-04-30 Glaxosmithkline Biolog Sa Vaccine
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
WO2012057904A1 (en) 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
BR112013011420A2 (pt) 2010-11-08 2016-08-02 Infectious Disease Res Inst vacinas compreendendo poliptídeos de nucleosídeo hidrolase não específica e esterol 24-c-metil-transferase (smt) para o tratamento e o diagnóstico de leishmaníase
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012072088A1 (en) 2010-12-02 2012-06-07 Bionor Immuno As Peptide scaffold design
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
AU2012204955B2 (en) 2011-01-06 2016-10-06 Bionor Immuno As Monomeric and multimeric immunogenic peptides
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
PL2667892T3 (pl) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa Schemat szczepień przeciwko rsv
US20140079732A1 (en) 2011-01-27 2014-03-20 Gamma Vaccines Pty Limited Combination vaccines
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
ES2716010T3 (es) 2011-03-29 2019-06-07 Uab Research Foundation Métodos y composiciones para la proteína IL-10 de citomegalovirus
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
WO2012149307A2 (en) 2011-04-27 2012-11-01 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
JP2014519819A (ja) 2011-05-13 2014-08-21 ノバルティス アーゲー 融合前ｒｓｖｆ抗原
KR20140033127A (ko) 2011-05-17 2014-03-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애에 대한 백신
WO2012170356A1 (en) 2011-06-04 2012-12-13 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
MX2013013627A (es) 2011-06-21 2014-04-25 Oncofactor Corp Composiciones y metodos para la terapia y diagnostico de cancer.
EP2726097A4 (en) * 2011-07-01 2015-03-11 Univ California HERPES VIRUS VACCINE AND METHOD OF USE
US10030052B2 (en) 2011-07-25 2018-07-24 Glaxosmithkline Biologicals Sa Parvovirus Vp1 unique region polypeptides and compositions thereof
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
US10206996B2 (en) 2011-08-22 2019-02-19 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
GB201114919D0 (en) 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
BR112014005406A2 (pt) 2011-09-09 2017-03-28 Nanobio Corp composição de vacina e respectivo uso
CN103917245B (zh) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
CN103930436A (zh) 2011-09-14 2014-07-16 诺华股份有限公司 大肠杆菌疫苗组合
LT2758432T (lt) 2011-09-16 2019-06-10 Ucb Biopharma Sprl Neutralizuojantys antikūnai prieš clostridium difficile tcda ir tcdb ekzotoksinus
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
PL2782598T3 (pl) 2011-11-23 2021-03-08 In3Bio Ltd. Rekombinowane białka i ich zastosowania terapeutyczne
EP2788477A2 (en) 2011-12-07 2014-10-15 Institut Pasteur Identification of a swine parecho-like virus and applications
IN2014CN04071A (nl) 2011-12-08 2015-10-23 Novartis Ag
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
WO2013111012A2 (en) 2012-01-27 2013-08-01 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
DK2811981T3 (da) 2012-02-07 2019-06-11 Infectious Disease Res Inst Forbedrede adjuvansformuleringer, der omfatter tlr4-agonister, og fremgangsmåder til anvendelse heraf
JP2015509713A (ja) 2012-02-24 2015-04-02 ノバルティス アーゲー 線毛タンパク質および組成物
US20130236484A1 (en) 2012-03-08 2013-09-12 Detectogen Inc. Leishmaniasis antigen detection assays and vaccines
ES2685612T3 (es) 2012-03-23 2018-10-10 Pitney Pharmaceuticals Pty Limited Inhibidores de cinasa para el tratamiento del cáncer
GB201205189D0 (en) 2012-03-23 2012-05-09 Glaxosmithkline Biolog Sa Novel medical use
ES2702278T3 (es) 2012-04-01 2019-02-28 Technion Res & Dev Foundation Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
EP2834265A4 (en) 2012-04-02 2015-10-14 Univ North Carolina METHODS AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
SG10201608980YA (en) 2012-04-26 2016-12-29 Novartis Ag Antigens and antigen combinations
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
JP6619648B2 (ja) 2012-05-16 2019-12-11 イミューン デザイン コーポレイション Ｈｓｖ−２のためのワクチン
MX2014014067A (es) 2012-05-22 2015-02-04 Novartis Ag Conjugado de serogrupo x de meningococo.
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
WO2013181696A1 (en) 2012-06-05 2013-12-12 The Australian National University Vaccination with interleukin-4 antagonists
IN2014KN02769A (nl) 2012-06-06 2015-05-08 Bionor Immuno As
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
KR20150036593A (ko) 2012-07-24 2015-04-07 사노피 파스퇴르 뎅기열 바이러스 감염 예방용 백신 조성물
WO2014019718A1 (en) 2012-08-01 2014-02-06 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
MX2015001557A (es) 2012-08-03 2015-10-08 Infectious Disease Res Inst Composiciones y metodos para tratar una infeccion activa por mycobacterium tuberculosis.
US9790176B2 (en) 2012-08-06 2017-10-17 Pitney Pharmaceuticals Pty Limited Compounds for the treatment of mTOR pathway related diseases
JP2014040396A (ja) * 2012-08-23 2014-03-06 Chemo-Sero-Therapeutic Research Institute 脂質異常症治療薬を含有するアジュバント組成物
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
EP2897635A1 (en) 2012-09-18 2015-07-29 Novartis AG Outer membrane vesicles
MX2015004171A (es) 2012-10-02 2015-10-22 Glaxosmithkline Biolog Sa Conjugados de sacaridos no lineales.
SG11201500978TA (en) 2012-10-03 2015-07-30 Glaxosmithkline Biolog Sa Immunogenic compositions
KR101819803B1 (ko) 2012-10-24 2018-01-17 플레이틀렛 타게티드 테라퓨틱스, 엘엘씨 혈소판 표적화 치료
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
WO2014083060A2 (en) 2012-11-30 2014-06-05 Novartis Ag Pseudomonas antigens and antigen combinations
LT2928489T (lt) 2012-12-05 2019-04-10 Glaxosmithkline Biologicals S.A. Imunogeninė kompozicija
NZ631536A (en) 2012-12-17 2016-12-23 Newsouth Innovations Pty Ltd Treatment of diseases involving mucin
WO2014100857A1 (en) 2012-12-24 2014-07-03 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
KR102391734B1 (ko) 2013-03-15 2022-04-29 인3바이오 리미티드 자기조립형 합성 단백질
US9909114B2 (en) 2013-03-28 2018-03-06 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
CN105209047B (zh) 2013-04-18 2020-08-18 免疫设计股份有限公司 用于癌症治疗的gla单一疗法
EP2994162B1 (en) * 2013-05-08 2021-04-07 Pharmgate Biologics Inc. Vaccine for pcv2 and mycoplasma
EP2996718B1 (en) 2013-05-15 2020-01-15 The Governors of the University of Alberta E1e2 hcv vaccines and methods of use
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
AU2014302282B2 (en) 2013-06-26 2018-09-13 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus vaccines
US10364277B2 (en) 2013-07-01 2019-07-30 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
US9975925B2 (en) 2013-08-28 2018-05-22 Glaxosmithkline Biologicals S.A. Influenza antigens and antibodies
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
CN105992770B (zh) 2013-11-01 2021-06-25 奥斯陆大学 白蛋白的变体及其用途
WO2015071769A2 (en) 2013-11-13 2015-05-21 University Of Oslo Outer membrane vesicles and uses thereof
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015077442A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Grass pollen immunogens and methods and uses for immune response modulation
WO2015077434A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Pan pollen immunogens and methods and uses for immune response modulation
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
AU2014373928C1 (en) 2013-12-31 2020-12-17 Access To Advanced Health Institute Single vial vaccine formulations
WO2015103104A1 (en) 2014-01-06 2015-07-09 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated salmonella enterica
EA201691452A1 (ru) 2014-01-21 2016-12-30 Иммьюн Дизайн Корп. Композиции для применения в лечении аллергических состояний
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20220080201A (ko) 2014-01-21 2022-06-14 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
WO2015131053A1 (en) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides derived from phl p and methods and uses thereof for immune response modulation
CA2944768C (en) 2014-04-03 2022-08-30 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
ES2860751T3 (es) 2014-05-28 2021-10-05 Agenus Inc Anticuerpos anti-GITR y procedimientos de uso de estos
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
JP6820830B2 (ja) 2014-07-18 2021-01-27 ユニヴァーシティ オブ ワシントン がんワクチン組成物およびその使用方法
WO2016012385A1 (en) 2014-07-21 2016-01-28 Sanofi Pasteur Vaccine composition comprising ipv and cyclodextrins
KR20170028442A (ko) 2014-07-23 2017-03-13 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
EP3204039B1 (en) 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
AU2015338859A1 (en) 2014-11-02 2017-06-01 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
BE1023004A1 (fr) 2014-12-10 2016-10-31 Glaxosmithkline Biologicals Sa Procede de traitement
WO2016109880A1 (en) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
KR102149760B1 (ko) 2015-01-15 2020-08-31 화이자 인코포레이티드 폐렴구균 백신에서 사용하기 위한 면역원성 조성물
MX2017010698A (es) 2015-02-20 2018-04-30 Univ Texas Metodos y composiciones para chlamydia atenuada como vacuna y vector.
EP4226937A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
US20180071380A1 (en) 2015-03-20 2018-03-15 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
US10821168B2 (en) 2015-03-26 2020-11-03 Gpn Vaccines Pty Ltd Streptococcal vaccine
US10682314B2 (en) 2015-05-26 2020-06-16 Ohio State Innovation Foundation Nanoparticle based vaccine strategy against swine influenza virus
WO2016193405A1 (en) 2015-06-03 2016-12-08 Affiris Ag Il-23-p19 vaccines
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
AU2016289497A1 (en) 2015-07-07 2017-12-07 Affiris Ag Vaccines for the treatment and prevention of IgE mediated diseases
TWI684461B (zh) 2015-07-21 2020-02-11 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
ES2607715B1 (es) 2015-10-01 2018-01-17 Solutex Na, Lcc Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
EP3733201A1 (en) 2016-01-19 2020-11-04 Pfizer Inc Cancer vaccines
GB201603625D0 (en) 2016-03-02 2016-04-13 Glaxosmithkline Biolog Sa Novel influenza antigens
WO2017156461A2 (en) 2016-03-10 2017-09-14 Aperisys, Inc. Antigen-binding fusion proteins with modified hsp70 domains
KR20230062894A (ko) 2016-03-14 2023-05-09 유니버시티에트 이 오슬로 변경된 FcRn 결합을 갖는 조작된 면역글로불린
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
WO2017167768A1 (en) 2016-03-28 2017-10-05 Glaxosmithkline Biologicals S.A. Novel vaccine composition
HUE059605T2 (hu) 2016-05-16 2022-11-28 Access To Advanced Health Inst TLR agonista tartalmú készítmény és használati eljárások
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
MX2018014270A (es) 2016-05-21 2019-02-14 Infectious Disease Res Inst Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
MX2018014399A (es) 2016-06-01 2019-06-06 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento.
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
EP3471761A2 (en) 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof
CN109863169A (zh) 2016-08-23 2019-06-07 葛兰素史密丝克莱恩生物有限公司 具有连接至不变链(cd74)的短片段的抗原的融合肽
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
BR112019004913B1 (pt) 2016-09-16 2022-07-12 Infectious Disease Research Institute Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
BR112019014510A2 (pt) 2017-01-13 2020-02-18 Agenus Inc. Receptores de célula t que se ligam ao ny-eso-1 e métodos de uso dos mesmos
RU2762723C2 (ru) 2017-01-20 2021-12-22 Пфайзер Инк. Иммуногенные композиции для применения в пневмококковых вакцинах
US11254712B2 (en) 2017-03-30 2022-02-22 The University Of Queensland Chimeric molecules and uses thereof
EP3600391A1 (en) 2017-03-31 2020-02-05 GlaxoSmithKline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
DK3618863T3 (da) 2017-05-01 2023-08-21 Agenus Inc Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
CA3066915A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
US11141377B2 (en) 2017-06-15 2021-10-12 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
JP2020527579A (ja) 2017-07-18 2020-09-10 イン３バイオ・リミテッドＩｎ３Ｂｉｏ Ｌｔｄ． 合成タンパク質およびその治療学的用途
WO2019034575A1 (en) 2017-08-14 2019-02-21 Glaxosmithkline Biologicals Sa METHODS OF AMPLIFYING IMMUNE RESPONSES
WO2019035963A1 (en) 2017-08-16 2019-02-21 Ohio State Innovation Foundation NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
EP3679062A1 (en) 2017-09-04 2020-07-15 Agenus Inc. T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
JP2020533338A (ja) 2017-09-07 2020-11-19 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ ワクチン分子
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
WO2019079594A1 (en) 2017-10-18 2019-04-25 The University Of North Carolina At Chapel Hill METHODS AND COMPOSITIONS FOR VACCINES AGAINST NOVOVIRUS AND DIAGNOSIS OF NOVOVIRUS
SG11202003800YA (en) 2017-11-03 2020-05-28 Takeda Vaccines Inc Zika vaccines and immunogenic compositions, and methods of using the same
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
WO2019239311A1 (en) 2018-06-12 2019-12-19 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
CA3109889A1 (en) 2018-08-23 2020-02-27 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3843782A1 (en) 2018-08-29 2021-07-07 Centre Hospitalier Universitaire Vaudois (CHUV) Ebola vaccine compositions and methods of using same
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
EP3890775A1 (en) 2018-12-06 2021-10-13 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
WO2020128012A1 (en) 2018-12-21 2020-06-25 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
WO2020178359A1 (en) 2019-03-05 2020-09-10 Glaxosmithkline Biologicals Sa Hepatitis b immunisation regimen and compositions
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3956666A1 (en) 2019-04-18 2022-02-23 GlaxoSmithKline Biologicals S.A. Antigen binding proteins and assays
KR20220125149A (ko) 2019-05-25 2022-09-14 액세스 투 어드밴스드 헬스 인스티튜트 애주번트 백신 에멀션을 분무 건조시키기 위한 조성물 및 방법
JP2022539067A (ja) 2019-06-25 2022-09-07 イン３バイオ・リミテッド 安定化キメラ合成タンパク質及びその治療的使用
AU2020318680A1 (en) 2019-07-21 2022-02-17 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
CN114667158A (zh) 2019-08-05 2022-06-24 葛兰素史克生物有限公司 免疫原性组合物
TW202122420A (zh) 2019-08-30 2021-06-16 美商艾吉納斯公司 抗ｃｄ９６抗體及其使用方法
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
EP3808765A1 (en) 2019-10-14 2021-04-21 ETH Zurich Cell line for tcr discovery and engineering and methods of use thereof
EP4051696A1 (en) 2019-11-01 2022-09-07 Pfizer Inc. Escherichia coli compositions and methods thereof
US20220396797A1 (en) 2019-11-15 2022-12-15 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
CA3165957A1 (en) 2020-01-24 2021-07-29 Thomas K. EQUELS Methods, compositions, and vaccines for treating a virus infection
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
MX2022010355A (es) 2020-02-21 2022-09-21 Pfizer Purificacion de sacaridos.
AU2021223184A1 (en) 2020-02-23 2022-08-18 Pfizer Inc. Escherichia coli compositions and methods thereof
CN115175924A (zh) 2020-02-26 2022-10-11 港大科桥有限公司 基于pd-1的针对冠状病毒感染的疫苗
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
EP4161570A1 (en) 2020-06-05 2023-04-12 GlaxoSmithKline Biologicals S.A. Modified betacoronavirus spike proteins
US20230256090A1 (en) 2020-06-29 2023-08-17 Glaxosmithkline Biologicals Sa Adjuvants
WO2022038157A1 (en) 2020-08-17 2022-02-24 Universität Basel Lfa-1 signalling mediator for use in cancer therapy
JP2023538665A (ja) 2020-08-24 2023-09-08 サノフィ パスツール インコーポレイテッド トコフェロール含有スクアレンエマルションアジュバントを有するｃｏｖｉｄ－１９ワクチン
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
US20230416309A1 (en) 2020-10-23 2023-12-28 Jiangsu Provincial Center For Disease Control And Prevention (Public Health Research Institute Of Ji Fusion protein and application thereof
CA3199610A1 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
US20240000912A1 (en) 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
EP4243863A2 (en) 2020-11-10 2023-09-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
AU2022223712A1 (en) 2021-02-19 2023-10-05 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
US20240148849A1 (en) 2021-02-22 2024-05-09 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
EP4313137A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals SA Immunogenic compositions
US20220387613A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202306969A (zh) 2021-05-28 2023-02-16 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
CA3222568A1 (en) 2021-06-28 2023-01-05 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023061993A1 (en) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides
CN118434441A (zh) 2021-11-18 2024-08-02 马特里瓦克斯公司 免疫原性融合蛋白组合物和其使用方法
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
GB202219228D0 (en) 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
EP0513861B1 (en) * 1987-11-03 1997-02-26 Syntex (U.S.A.) Inc. Vaccine adjuvant comprising a tetra-polyol
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0382271T3 (da) * 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler som adjuvanser i vacciner
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
NZ238731A (en) * 1990-06-27 1996-02-27 Univ Emory Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide
EP0489153B1 (en) * 1990-06-29 1999-10-13 Chiron Corporation Vaccine compositions containing liposomes
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
KR100194079B1 (ko) * 1990-09-28 1999-06-15 장 스테판느 Hiv 감염 예방 또는 치료용 제약학적 조성물 및 이의 제조방법
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
PH30906A (en) 1991-07-25 1997-12-23 Idec Pharma Corp Induction of cytotoxic t-lymphocyte responses.
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
PL170980B1 (pl) * 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
CZ289476B6 (cs) * 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby
ATE196737T1 (de) * 1993-05-25 2000-10-15 American Cyanamid Co Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
US20060182753A1 (en) 2006-08-17
DE69433750D1 (de) 2004-06-03
AU6803198A (en) 1998-07-09
EP0868918B1 (en) 2004-04-28
DK1327451T3 (da) 2007-08-20
LU91485I2 (fr) 2008-12-15
KR100350965B1 (ko) 2003-02-25
US20070134268A1 (en) 2007-06-14
EP0735898A1 (en) 1996-10-09
DE69434956T2 (de) 2008-01-17
NL300363I1 (nl) 2009-01-05
JP4126079B2 (ja) 2008-07-30
EP0868918A3 (en) 2000-04-26
US6623739B1 (en) 2003-09-23
ATE265228T1 (de) 2004-05-15
NZ329661A (en) 2005-03-24
ES2129801T3 (es) 1999-06-16
US7169391B2 (en) 2007-01-30
LU91486I2 (fr) 2008-12-15
HK1057991A1 (en) 2004-04-30
EP0735898B1 (en) 1999-03-10
PT1327451E (pt) 2007-07-23
CY2530B1 (en) 2006-04-12
GB9326253D0 (en) 1994-02-23
AU1316695A (en) 1995-07-10
CN1086589C (zh) 2002-06-26
AU705521B2 (en) 1999-05-27
JP2006249080A (ja) 2006-09-21
SI0735898T1 (en) 1999-06-30
AU6803298A (en) 1998-07-09
WO1995017209A1 (en) 1995-06-29
SI1327451T1 (sl) 2007-08-31
HK1012243A1 (en) 1999-07-30
EP0868918A2 (en) 1998-10-07
JP4126067B2 (ja) 2008-07-30
AU1316495A (en) 1995-07-10
DE69434956D1 (de) 2007-05-31
PT868918E (pt) 2004-08-31
DK0735898T3 (da) 1999-08-23
DK0868918T3 (da) 2004-08-16
DE69417063T2 (de) 1999-10-28
EP1327451B1 (en) 2007-04-18
ES2285036T3 (es) 2007-11-16
CY2593B2 (en) 2009-11-04
CA2179779C (en) 2010-04-20
US7510698B2 (en) 2009-03-31
SG73578A1 (en) 2000-06-20
ZA9410176B (en) 1995-11-17
NZ277802A (en) 1998-04-27
DE122008000055I1 (de) 2009-02-19
DE69417063D1 (de) 1999-04-15
ATE177322T1 (de) 1999-03-15
DE122008000054I1 (de) 2009-02-19
AU687494B2 (en) 1998-02-26
JPH09506887A (ja) 1997-07-08
ATE359818T1 (de) 2007-05-15
DE69433750T2 (de) 2005-08-04
EP1792628A1 (en) 2007-06-06
AU705519B2 (en) 1999-05-27
EP1327451A1 (en) 2003-07-16
CN1138298A (zh) 1996-12-18
ES2219837T3 (es) 2004-12-01
US6146632A (en) 2000-11-14
CA2179779A1 (en) 1995-06-29
SG49257A1 (en) 1998-05-18
WO1995017210A1 (en) 1995-06-29
GR3029750T3 (en) 1999-06-30
SI0868918T1 (en) 2004-08-31
US7029678B2 (en) 2006-04-18
JP4125781B2 (ja) 2008-07-30
JP2007231029A (ja) 2007-09-13
HK1021504A1 (en) 2000-06-16
US20040043038A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
NL300362I1 (nl) Vaccin omvattende olie/water-emulsie met tocoferolen squaleen
MX9303773A (es) Composicion de vacuna que comprende un antigeno y/o una composicion antigenica de qs21 y monofosforil-lipido a 3-des-o-acilado y proceso para su elaboracion.
GR3015438T3 (en) Tocols as adjuvant in vaccine.
DE69131709D1 (de) Liposomen enthaltende impfstoffzusammensetzungen